Coordinatore | UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 3˙090˙797 € |
EC contributo | 3˙090˙797 € |
Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
Code Call | FP7-PEOPLE-2012-ITN |
Funding Scheme | MC-ITN |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-11-01 - 2016-10-31 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | coordinator | 981˙389.06 |
2 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 516˙977.84 |
3 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 487˙392.70 |
4 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 297˙634.88 |
5 |
FONDAZIONE TELETHON
Organization address
address: VIA VARESE 16/B contact info |
IT (ROMA) | participant | 282˙524.16 |
6 |
UNIVERSITEIT GENT
Organization address
address: SINT PIETERSNIEUWSTRAAT 25 contact info |
BE (GENT) | participant | 272˙026.20 |
7 |
AVACTA LIFE SCIENCES LIMITED
Organization address
address: STREET 5 UNIT 651 THORP ARCH ESTATE contact info |
UK (WETHERBY) | participant | 252˙852.16 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Eye research has often blazed a trail for other disciplines to follow, giving a lead in neuroscience, genetics, the development of gene- and stem-cell therapies and other important areas of medical research. In recent years, geneticists have made many remarkable discoveries of relevance both to normal human vision and the development of inherited retinal pathology. However the genes and mutations identified account for only a proportion of cases of inherited retinal degeneration, and recent discoveries hint at new classes of mutations which are either largely undetected or the significance of which is missed by conventional genetics. In addition, for those genes implicated there often remains a black box between mutations and disease; how do defects in a given protein manifest symptoms in the eye and what underlies the huge variation in symptoms, severity and response to treatment? The objectives of EyeTN are twofold; to address these knowledge gaps through cutting edge research using novel techniques, including transcriptomics analyses, whole genome and single target RNAi, the development of animal and cell-based disease models, stem cell biology, bioinformatics and hands on experience of pharmaceutical research with direct translational targets; and to give the next generation of European ophthalmic researchers unparalleled opportunities to train with a consortium of the best inherited blindness research labs in the world. The Network spans academic, healthcare and commercial research sectors and is already well established with many existing collaborations. All fellows will carry out one or more components of their research and training in a commercial environment and attend a workshop on translating ideas and discoveries into commercially viable Bioscience produces and therapies, fostering an entrepreneurial mindset and ensuring that we train a pool of researchers who are able to communicate effectively with both academic and commercial bioscience colleagues.'